CompletedNot Applicable

Evaluation of the Effectiveness of the Nebulization Bronchodilators Under High Nasal Flow Humidified

France25 participantsStarted 2016-06

Plain-language summary

The principal objective is to show noninferiority of nebulized salbutamol through the high flow nasal system moistened AIRVO ™ 2 in terms of reversibility of airflow obstruction compared to nebulization by the usual method (spray mask).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. A report FEV / FVC less than 60% prior to bronchodilator treatment AND
✓. A positive reversal test defined by FEV variation of over 12 % and 200 mL after administration of inhaled salbutamol

What they're measuring

Increased expiratory volume in one second ( FEV )

Timeframe: measured before and after nebulization of salbutamol at 0 minute and 15 minutes after nebulization of salbutamol

Trial details

NCT IDNCT02812979

SponsorUniversity Hospital, Tours

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-04-27

View on ClinicalTrials.gov More Chronic Obstructive Pulmonary Disease trials